Jonathan N. Rubin Sells 17,443 Shares of Magellan Health Inc (MGLN) Stock
Magellan Health Inc (NASDAQ:MGLN) CFO Jonathan N. Rubin sold 17,443 shares of Magellan Health stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $96.07, for a total value of $1,675,749.01. Following the sale, the chief financial officer now owns 43,890 shares in the company, valued at approximately $4,216,512.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Magellan Health Inc (NASDAQ MGLN) traded up $0.60 on Wednesday, reaching $97.50. The company’s stock had a trading volume of 153,815 shares, compared to its average volume of 172,350. Magellan Health Inc has a 12 month low of $64.05 and a 12 month high of $99.80. The stock has a market cap of $2,321.28, a price-to-earnings ratio of 25.73, a PEG ratio of 1.13 and a beta of 0.53. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.28 and a quick ratio of 2.21.
Magellan Health (NASDAQ:MGLN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $1.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.24. Magellan Health had a return on equity of 9.20% and a net margin of 1.68%. The company had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the company earned $1.39 EPS. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. equities analysts predict that Magellan Health Inc will post 5.19 EPS for the current fiscal year.
MGLN has been the topic of a number of research reports. ValuEngine raised Magellan Health from a “hold” rating to a “buy” rating in a report on Sunday. BidaskClub lowered Magellan Health from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 19th. KeyCorp set a $105.00 price target on Magellan Health and gave the stock a “buy” rating in a report on Friday, December 1st. Jefferies Group reissued a “buy” rating and set a $94.00 price target on shares of Magellan Health in a report on Friday, October 13th. Finally, Raymond James Financial reissued a “hold” rating on shares of Magellan Health in a report on Saturday, December 2nd. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $96.00.
Magellan Health Company Profile
Magellan Health, Inc is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC).
Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with MarketBeat.com's FREE daily email newsletter.